Daily Biotech Movers — 2026-09-25: Every Name on the Leaderboard Traded Below $5 While Devices and Diagnostics Were Bid

Friday, September 25, 2026 was a day the sector lost money and the index did not. Across 572 tracked public biotech and life-sciences companies, 360 finished lower against 198 advancers — a decliner-to-advancer ratio of 1.82-to-1, nearly half again as wide as Thursday’s 1.35-to-1. The median move was -0.82% and the mean -0.98%, with a standard deviation of 3.71%. 60 companies moved at least 5% and 75 were anomaly-flagged once volume-only spikes are counted — down sharply from Thursday’s 108 and 126, which is the first clue that this was not a repeat of the previous session’s two-sided fireworks. Fourteen names closed exactly unchanged.

What makes the session worth reading closely is the split underneath it. The small-cap biotech index proxy closed down 0.65%, while the broad healthcare proxy gained 0.50% and the S&P 500 proxy finished up 0.54% — so healthcare as an asset class made money on a day when the typical tracked company lost eight-tenths of a percent. The gap was not random: it was surgical and implantable devices and diagnostics being bid at the same time as clinical-stage small caps and biologics were sold. And then there is the detail that frames everything below: all six of the day’s largest movers closed under $5 a share — a $1.27 bounce, a $1.03 strategic-capital print, a $3.25 collapse, and three names between $1.55 and $4.88. On a day when the revenue-positive, index-weighted end of healthcare rose, the entire leaderboard was microcap.

The Distribution

Measure	September 25 reading
Tracked / priced	572
Directional moves	558 (198 up, 360 down), 14 unchanged
Up / down ratio	1.82-to-1 decliners
Mean / median	-0.98% / -0.82%
Standard deviation	3.71%
Average advancer / decliner	+2.09% / -2.70%
Price moves of at least 5%	60
Anomaly-flagged (incl. volume-only)	75
Stealth names (|move| < 3% on 3x+ volume)	3

Two features of that table matter. The first is that the tails have compressed. On Thursday the average advancer gained +3.58% and the average decliner lost -3.42% on a 6.70% standard deviation; today the average advancer gained +2.09% and the average decliner lost -2.70% on a 3.71% standard deviation. That is a narrower, more one-sided tape: fewer violent repricings, and the ones that happened were concentrated on the losing side. The second is the breadth arithmetic: Thursday had 237 advancers; today had 198. Thursday’s bid was thin and narrow; today’s was thinner still, and the sectors doing the advancing were not the sectors owning the marginal research dollar.

The sector table makes the rotation legible, and it is unusually clean at the top. Devices — Implants +2.11% (n=10) and Devices — Imaging +1.91% (n=8) led every bucket, followed by Devices — Measurement +0.98% (n=4), Diagnostics +0.33% (n=30) and Devices — Surgical +0.02% (n=29). On the losing side the pattern is the inverse and wider: Small Molecule Pharma -1.25% (n=152), Biologics -1.48% (n=86), Drug Delivery/Formulation -2.07% (n=31), RNA, Peptide & Gene Therapy -1.16% (n=27), Antibodies -1.02% (n=42), Generic Drugs -1.76% (n=5), Cannabis-related -2.10% (n=5) and AI / Machine Learning -2.19% (n=6). The largest bucket on the board — small-molecule pharma, which is where most of the tracked clinical-stage universe sits — was the second-largest decliner by weight. The single worst number in the table, Northern California -10.61% (n=3), is not a sector at all: it is three companies whose categorisation carries a region rather than a therapeutic area, and one large loser inside it drags the bucket. Read it as a data artefact, not as a regional rotation.

The stealth set, by contrast, was almost empty and pointed up: Kodiak Sciences (-2.62% on 3.19x), Arbutus Biopharma (-0.61% on 3.12x) and SINTX Technologies (+0.53% on 3.09x). Three names clearing a 3x volume filter while the median company fell -0.82% is a quiet bid arriving in specific places rather than a broad accumulation signal — and it is worth noting that two of the three closed lower on the day.

The 6 Classes of Mover Signal

1. Halt-release and reverse-split-adjacent mechanics. Present, and it explains the strangest print on the board. Curanex Pharmaceuticals (+13.23% on 2.51x) is a post-1-for-20-reverse-split equity that regained Nasdaq minimum-bid-price compliance in early September, and it advanced double digits on 71,261 shares. Scinai Immunotherapeutics (-16.67% on 0.05x) lost seven-eighths of nothing: 120,352 shares traded in a session it fell 16.7%, which is a book without depth rather than a verdict. Tenon Medical (+5.74% on 0.14x) is the same asymmetry upward, a sub-$4 name moving on a fifth of normal turnover.

2. Single-stock clinical, regulatory or commercial catalyst. Present on both sides. Tvardi Therapeutics (+19.81% on 4.12x) moved on a September 24 preclinical publication supporting its oral STAT3 inhibitors in ulcerative colitis — a real disclosure, but one that arrived the previous session and that the tape had sold into. Elsewhere the class is visible without a same-day release: Adicet Bio (+9.07% on 4.67x), Actuate Therapeutics (+9.68%), Mereo BioPharma (+9.63%), STAAR Surgical (+7.49%) and CVRx (+6.72%) all cleared anomaly thresholds on the winning side, while Biomea Fusion (-11.41% on 1.28x), Neurogene (-9.41%), Beyond Air (-9.81%) and aTyr Pharma (-9.66% on 8.3 million shares) cleared them on the losing side.

3. Buyout and strategic capital. Present, and it produced the day’s cleanest institutional print. Onconetix (+13.07% on 26.08x) traded 47.7 million shares after SRX Global Inc. (NYSE: SRXH) disclosed an investment in the company in anticipation of its Realbotix acquisition closing. A named buyer validating a pending deal structure is a fundamental repricing event, and the 26-times-normal turnover on a $1.03 equity is what that looks like when the buyer is public about why it is buying.

4. Sector rotation. Present, and the defining feature of the session. The XLV +0.50% against XBI -0.65% pair says capital is in revenue-positive healthcare and medtech rather than high-beta clinical-stage biotech, and the sector table confirms it from the inside: devices and diagnostics occupy every slot in the top five while small-molecule pharma, biologics and drug delivery occupy the bottom. This is the same rotation Thursday began — with one difference worth naming. Thursday the rotation was into life-science tools and genomics platforms; today it was into devices and diagnostics, and the tools complex that rallied to 52-week highs on Thursday does not repeat today.

5. Sell-the-news and prior-cycle profit-taking. Present, and it supplied the entire losing tail. Profusa (-28.05% on 0.46x) gave back the bulk of Thursday’s +41.46% on below-average volume. Artelo Biosciences (-12.19% on 0.25x), Surrozen (-12.29% on 3.32x) and Vistagen Therapeutics (-7.46% on 0.25x) are the same construction applied to names that had already run — Surrozen still shows +98.8% on five days, Artelo +30.2%, Vistagen +26.3%. LeonaBio (-34.87% on 5.07x) belongs to the dilution half of this class: a warrant window opened the previous week and the shares spent the week finding out what the market would pay for it.

6. Stealth accumulation and distribution. Barely present — three names, mixed direction, and none of them large. The information in Kodiak Sciences (-2.62% on 3.19x), Arbutus Biopharma (-0.61% on 3.12x) and SINTX (+0.53% on 3.09x) is the ratio, not the price: a 3x print that leaves the quote unchanged is a claim about who is trading rather than about what the company is worth.

Top 3 Winners — What Drove Them

TVRD — Tvardi Therapeutics — +19.81% on 4.12x volume

Tvardi closed at $1.27 on 657,706 shares — 4.12x its 30-day average, against a $1.06 prior close, having traded between $1.07 and $1.28 — a 0.8%-of-range print that sits within four cents of its recorded 52-week low of $0.93, with five-day momentum still -34.6%. Signal class: Class 2 single-stock catalyst landing on a washed-out tape. The disclosure is a preclinical publication dated September 24: new data supporting the potential of the company’s oral STAT3 inhibitors, including TTI-109, in ulcerative colitis GlobeNewswire — New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC); Yahoo Finance — preclinical data further support potential; TipRanks — Tvardi announces publication of preclinical data on STAT3 inhibitor. The caution is in the calendar, not the science: Thursday’s tape sold this same news, the shares were removed from the S&P Global BMI index on September 21, and a preclinical readout in a $1.27 equity is the weakest instrument in the sequence MarketScreener — Tvardi Therapeutics dropped from S&P Global BMI Index. Four times normal turnover into a five-day drawdown of -34.6% reads as a reversal leg — the buyer arriving where the index seller had finished — rather than a re-rating.

CURX — Curanex Pharmaceuticals — +13.23% on 2.51x volume

Curanex closed at $4.88 on 71,261 shares — 2.51x its 30-day average, against a $4.31 prior close, inside a $4.40–$5.00 session range and roughly 7.5% up its 52-week range, with five-day momentum of -3.3%. Signal class: no clean same-day catalyst — post-reverse-split thin-float mechanics. Nothing has been published in the trailing four trading days; the most recent item is the September 4–5 disclosure that the company regained Nasdaq minimum-bid-price compliance following a 1-for-20 reverse stock split TradingView — Curanex Pharmaceuticals regains Nasdaq compliance after 1-for-20 reverse split; MiniChart — Curanex Pharmaceuticals Regains Nasdaq Minimum Bid Price Compliance. The arithmetic is the story: 71,000 shares is the entire volume behind a 13% move, and on a post-split float that small the printed percentage says more about the depth of the book than about the company’s prospects. Prior-cycle / mechanical move — flagged.

ONCO — Onconetix — +13.07% on 26.08x volume

Onconetix closed at $1.03 on 47,717,395 shares — 26.08x its 30-day average, against a $0.9109 prior close, having traded as high as $1.42 intraday, with five-day momentum at +37.3%. Signal class: Class 3 buyout / strategic capital. After the close on September 24, SRX Global Inc. told its own shareholders it has added an investment in Onconetix in anticipation of Onconetix’s previously announced agreement to acquire Realbotix LLC, describing the target’s Vinci AI vision system — a patented robotic eyeball platform — as undervalued and misunderstood with defence applications SRX Global — Shareholders update on liquidation of two portfolio investments and adds an investment in Onconetix; Yahoo Finance — SRX Global Makes Investment in Onconetix; MarketChameleon — Onconetix rallies after SRX Global adds a stake tied to Realbotix’s in-eye AI vision system; StreetInsider — SRX Global provides shareholders with update. The chain runs back a fortnight: on September 14 Onconetix agreed to lend Realbotix up to $5 million, half of it funded, as merger bridge capital TradingView — Onconetix provides up to $5 million unsecured loan to Realbotix. This is a capital-structure catalyst rather than a clinical one, which is exactly why 26x volume printed: what was repriced is the credibility of the buyer, not the science of the asset.

Top 3 Losers — What Drove Them

LONA — LeonaBio — -34.87% on 5.07x volume

LeonaBio closed at $3.25 on 349,439 shares — 5.07x its 30-day average, against a $4.99 prior close, trading a $3.15–$5.59 range and printing a new 52-week low beneath its recorded $3.60 floor, with five-day momentum at -28.2% and the close now roughly 49% below the exercise price of the warrants at the centre of the story. Signal class: Class 5 sell-the-news / dilution unwind on a prior-cycle catalyst — flagged. On September 18 the Series A common warrants from the company’s December 2025 private placement — covering 23,031,494 shares at a $6.35 strike — became exercisable through October 19, 2026, and the company framed the window as access to up to $146.2 million of new capital if exercised in full for cash TipRanks — LeonaBio Opens Warrant Exercise Window for New Capital; The Globe and Mail — LeonaBio Opens Warrant Exercise Window for New Capital; PennyStocksUnited — LeonaBio Series A Warrants Become Exercisable, $146.2M Capital; Panabee — LeonaBio Warrants Become Exercisable, Targeting $146 Million Cash Infusion. No same-day headline exists: this is the unwind leg of a slide that took the shares from $6.79 on September 20 to $4.99 on Thursday and $3.25 today. The mechanism is arithmetic. The programme behind the equity is real — lasofoxifene in a Phase 3 trial in ESR1-mutated metastatic breast cancer, with 495 of about 600 patients enrolled — which is precisely why a warrant struck at $6.35 mattered to the capital plan LeonaBio — Pipeline. Once the stock trades below the strike, a cash exercise that would fund the treasury becomes an out-of-the-money overhang and the marginal holder sells the shares instead.

PFSA — Profusa — -28.05% on 0.46x volume

Profusa closed at $2.18 on 2,534,629 shares — 0.46x its 30-day average, against a $3.03 prior close, a $2.10–$2.75 session range, and 38% above its recorded 52-week low of $1.58 — with five-day momentum still up +68.3%. Signal class: Class 5 sell-the-news — the catalyst belongs to the previous session. On September 24 the company announced that its quality-management system has received ISO 13485 certification, advancing the Lumee oxygen platform toward CE marking, with the certification decision expected in early October — and the stock ran +41.46% on that disclosure RTTNews — Profusa Advances Lumee Oxygen Platform Toward CE Mark; Benzinga — Micro-cap Profusa navigates European regulatory hurdles to advance oxygen-monitoring tech; GlobeNewswire via MSN — Profusa ISO 13485 Certification Decision Advances Lumee Oxygen Platform Toward CE Mark. Today produced no new disclosure. The distinguishing feature is the turnover: a -28% decline on less than half normal volume is profit-taking in a $2 microcap that had just doubled, not institutional distribution — and the company’s September capital raising was a $350,000 senior secured convertible note issued on September 16 at a $4.28 conversion price that now sits well above the market TradingView — Profusa raises $350,000 via senior secured convertible note. Prior-cycle catalyst — flagged.

SCNI — Scinai Immunotherapeutics — -16.67% on 0.05x volume

Scinai closed at $1.55 on just 120,352 shares — 0.05x its 30-day average, against a $1.86 prior close, a $1.55–$1.73 range that closed on the session low, roughly 8% up its 52-week range, with five-day momentum still +14.8%. Signal class: Class 5 dilution / resale-registration overhang. On September 24–25 the company filed a prospectus covering the resale of up to 2,706,450 American Depositary Shares held by YA II PN, Ltd., in a transaction whose proceeds go to the selling shareholder rather than to the company, with the filing’s own framing putting the full issuance under its funding arrangement at approximately 66.67% of its depositary shares ScanX — Scinai files prospectus for resale of 2.7 million ADSs; StockTitan — Scinai updates funding deal, full issuance would represent about 66.67% of Scinai’s depositary shares. The setup was already in place: September 21 brought the regained minimum-bid-price compliance notice that produced the five-day gain now being given back PR Newswire — Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement; TipRanks — Scinai Immunotherapeutics Restores Nasdaq Minimum Bid Price Compliance. A -16.7% move on five percent of typical volume is a liquidity air pocket rather than a mass exit — but the two-thirds-of-the-structure registration is the fundamental part of the story, and it is what the compliance rally was always going to have to absorb.

The Cross-Cutting Pattern

The pattern is a rotation with a shrinking bid on the speculative side, and the single cleanest way to see it is the index pair. The broad healthcare proxy gained 0.50% and the S&P 500 proxy gained 0.54% while the small-cap biotech proxy lost 0.65% and the median tracked company lost 0.82%. Behind those numbers, devices and diagnostics took four of the five top sector slots while the two heaviest buckets in the tracked universe — Small Molecule Pharma (n=152) and Biologics (n=86) — were down -1.25% and -1.48%. Capital is not leaving healthcare; it is choosing the revenue-positive end of it, and the pure-research end is paying for that choice.

The second theme is what happens to a thin bid when it is asked to hold more than one day. Thursday’s two largest gainers were Profusa (+41.46%) and Surrozen (+107.86%). Today Profusa lost -28.05% and Surrozen lost -12.29%, on 0.46x and 3.32x volume respectively, while Artelo (-12.19% on 0.25x) and Vistagen (-7.46% on 0.25x) — Thursday’s other spikes — unwound on a quarter of normal turnover. Four names, four give-backs, no company-specific bad news among them. That is the signature of a bid that stopped arriving rather than one that was withdrawn, and it is the most important thing to understand about a day with 60 moves of 5% or more but only 75 anomaly flags: the amplitude is there, the participation is not.

The third theme is that the winners were not a sentiment signal either. Tvardi’s +19.81% is a $1.27 equity four cents off its low, reversing after an index deletion. Curanex’s +13.23% is 71,000 shares in a post-split float. Onconetix’s +13.07% is the only one of the three with a genuinely new fact attached to it — a public buyer validating a pending acquisition — and even that arrived on an equity whose 52-week low is $0.59. Read together with the losing tail, the session is best described as microcap flow rotating among itself while the index-weighted parts of healthcare absorbed the day’s actual money.

The 5 Data Points That Matter

1. Percentage change versus the tape. With a -0.82% median, the six leaderboard names are 12- to 34-point divergences, and the sector-relative gaps isolate what was idiosyncratic. TVRD +19.81% against a -1.25% Small Molecule Pharma (n=152) bucket is a 21-point inversion; LONA -34.87% against the same bucket is a 34-point one. The two names that decoupled hardest from their own group — ONCO +13.07% and PFSA -28.05% — did so on opposite logic: one is a new fact, the other is the absence of one.

2. Volume ratio. The two heaviest ratios on the board are the two most interesting prints. ONCO at 26.08x on 47.7 million shares is volume confirming that something was repriced. NovaBridge Biosciences at 22.31x on a -4.83% close is the opposite: an $1.44 equity turning over 22 times normal while the price falls, which is a distribution signature rather than a catalyst. Then the leaders thin out fast — LONA 5.07x, ACET 4.67x, TVRD 4.12x, SRZN 3.32x — and the two remaining leaderboard names are the tell: PFSA at 0.46x and SCNI at 0.05x fell 28% and 17% on below-average volume. Declines of that size without a seller’s footprint are the absence of a bid, not the arrival of one.

3. Five-day momentum. This column separates an event from a trend, and today it belongs to the prior-cycle camp. PFSA +68.3% against a -28.05% day, SRZN +98.8% against -12.29%, ARTL +30.2% against -12.19%, VTGN +26.3% against -7.46% — four names unwinding inside their own week. TVRD -34.6% against +19.81% is the mirror image, the first up-day inside a decline, and it is the one print on the board that could mark a turn rather than a fade. Only ONCO (+37.3% on +13.07%) shows genuine continuation, and it is the only one with a reason to.

4. Position in range and absolute price. Friday’s leaderboard is a single price band: six names, all below $5, and four of them under $2.50. LONA closed at a new 52-week low, TVRD within four cents of its low, and SCNI and CURX sat at 8% and 7.5% of their ranges. That is the opposite of Thursday, when the tools complex printed fresh 52-week highs. The index-level reading says healthcare was bought; the range reading says what was bought was not the kind of equity that appears on this board.

5. Cash and dilution context. This is the differentiator, and it explains why the losing side looked the way it did. LONA is carrying 23,031,494 warrants struck at $6.35 against a $3.25 close — a financing instrument that has become a liability. SCNI has registered resale paper equal to about 66.67% of its depositary structure in a shareholder’s hands. PFSA raised $350,000 in mid-September against a $4.28 conversion price it now trades below. Against that, ONCO’s catalyst is a third party putting money in, and TVRD’s is a publication that costs nothing to file. The asymmetry that organised the whole day is the same one that organised Thursday: capital released versus capital required.

The five-point summary: read ONCO as a genuine strategic-capital repricing of a sub-$1 equity’s deal credibility; read TVRD as a first reversal day inside a -34.6% drawdown with a preclinical disclosure dated the prior session; read CURX as a post-reverse-split float moving 13% on 71,000 shares with no news; read LONA as a warrant-overhang unwind that has now broken below its own strike; read PFSA as the give-back leg of the previous session’s CE-mark spike on half of normal volume; and read SCNI as a two-thirds-of-structure dilution registration hitting a book with no depth.

What This Synthesis Will and Won’t Tell You

This is a one-day reading and should be read as one. It tells you what moved and why: the 75 anomaly-flagged names, the six data-defined top movers, the signal class behind each, and the cross-cutting pattern — a rotation inside healthcare in which the index-level proxies rose while the median tracked company fell, devices and diagnostics took every slot at the top of the sector table, the two heaviest research buckets kept bleeding, and every name on the leaderboard traded below $5. It does not tell you what happens next: whether the XLV-over-XBI preference persists or reverses if rate expectations change; whether Onconetix’s Realbotix acquisition closes and whether SRX Global’s disclosed stake is joined by others or is a single buyer’s position; whether Tvardi’s STAT3 ulcerative-colitis data becomes a clinical programme with a timeline rather than a journal publication; whether Profusa’s ISO 13485 certification is finalised in early October and converts into CE marking; whether LeonaBio’s warrant window closes on October 19 without the cash exercise the company’s framing implied; or whether Scinai’s resale registration is absorbed without further pressure on a register that has already been through a bid-price cure.

The honest limits are three. The catalyst investigation covers the six data-defined top movers only — the rest of the anomaly board, including KALA BIO -15.07%, Cellectar Biosciences -13.25%, Biomea Fusion -11.41%, Beyond Air -9.81%, aTyr Pharma -9.66% and Palisade Bio -7.64% on the downside, and Adicet Bio +9.07%, Actuate +9.68%, Mereo +9.63%, STAAR Surgical +7.49%, CVRx +6.72% and Kestra Medical +5.36% on the upside, carries stories that are noted but not investigated. Several genuinely large moves sit outside the data-defined top three on either side. Second, two of the six leaderboard names had no clean same-day catalyst and this synthesis labels them mechanical rather than inventing narratives for them. Third, all six are sub-$5 equities and three of them are sub-$2, where a single session’s percentage move is a statement about a float rather than about a business — and a -0.82% median on 360 decliners beside a +0.50% healthcare proxy says more about which part of the sector owns the marginal dollar than about the clinical or commercial prospects of the companies involved.

---

This is editorial analysis, not investment advice. Single-day returns reflect regular-session closing prices on 2026-09-25 and will change with market conditions, clinical readouts, financing terms, and regulatory events. Microcap and clinical-stage names can experience rapid reversals; readers should review the underlying disclosures before drawing conclusions about momentum durability.

Generated 2026-09-25 PT (post-market, after the 4 PM ET close). Market data compiled from public quote and historical market-data feeds; sector categorization from public company filings and listings; company backgrounds compiled from public investor disclosures and press releases. For the prior synthesis, see Daily Biotech Movers — 2026-09-24.